Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ebola vaccine R&D: Filling the knowledge gaps.
Medaglini D, Harandi AM, Ottenhoff TH, Siegrist CA; VSV-Ebovac Consortium. Medaglini D, et al. Sci Transl Med. 2015 Dec 9;7(317):317ps24. doi: 10.1126/scitranslmed.aad3106. Sci Transl Med. 2015. PMID: 26659569 Free PMC article. Review.
Immunity against HIV/AIDS, malaria, and tuberculosis during co-infections with neglected infectious diseases: recommendations for the European Union research priorities.
Boraschi D, Abebe Alemayehu M, Aseffa A, Chiodi F, Chisi J, Del Prete G, Doherty TM, Elhassan I, Engers H, Gyan B, Harandi AM, Kariuki T, Kironde F, Kouriba B, Langhorne J, Laskay T, Medaglini D, Olesen O, Onyebujoh P, Palma C, Sauerwein R, Sibanda E, Steinhoff U, Tagliabue A, Thiel A, Vahedi M, Troye-Blomberg M. Boraschi D, et al. Among authors: medaglini d. PLoS Negl Trop Dis. 2008 Jun 25;2(6):e255. doi: 10.1371/journal.pntd.0000255. PLoS Negl Trop Dis. 2008. PMID: 18575596 Free PMC article.
Vaccine adjuvants: a priority for vaccine research.
Harandi AM, Medaglini D, Shattock RJ; Working Group convened by EUROPRISE. Harandi AM, et al. Among authors: medaglini d. Vaccine. 2010 Mar 11;28(12):2363-6. doi: 10.1016/j.vaccine.2009.12.084. Epub 2010 Jan 9. Vaccine. 2010. PMID: 20064476
Mucosal adjuvants.
Harandi AM, Medaglini D. Harandi AM, et al. Among authors: medaglini d. Curr HIV Res. 2010 Jun;8(4):330-5. doi: 10.2174/157016210791208695. Curr HIV Res. 2010. PMID: 20353395 Review.
Assessment of mucosal immunity to HIV-1.
Jespers V, Harandi AM, Hinkula J, Medaglini D, Le Grand R, Stahl-Hennig C, Bogers W, El Habib R, Wegmann F, Fraser C, Cranage M, Shattock RJ, Spetz AL. Jespers V, et al. Among authors: medaglini d. Expert Rev Vaccines. 2010 Apr;9(4):381-94. doi: 10.1586/erv.10.21. Expert Rev Vaccines. 2010. PMID: 20370549 Free article. Review.
ADITEC: joining forces for next-generation vaccines.
Rappuoli R, Medaglini D. Rappuoli R, et al. Among authors: medaglini d. Sci Transl Med. 2012 Apr 4;4(128):128cm4. doi: 10.1126/scitranslmed.3003826. Sci Transl Med. 2012. PMID: 22491948
A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.
Huttner A, Combescure C, Grillet S, Haks MC, Quinten E, Modoux C, Agnandji ST, Brosnahan J, Dayer JA, Harandi AM, Kaiser L, Medaglini D, Monath T; VEBCON and VSV-EBOVAC Consortia; Roux-Lombard P, Kremsner PG, Ottenhoff TH, Siegrist CA. Huttner A, et al. Among authors: medaglini d. Sci Transl Med. 2017 Apr 12;9(385):eaaj1701. doi: 10.1126/scitranslmed.aaj1701. Sci Transl Med. 2017. PMID: 28404856 Free PMC article.
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.
Huttner A, Agnandji ST, Combescure C, Fernandes JF, Bache EB, Kabwende L, Ndungu FM, Brosnahan J, Monath TP, Lemaître B, Grillet S, Botto M, Engler O, Portmann J, Siegrist D, Bejon P, Silvera P, Kremsner P, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia. Huttner A, et al. Lancet Infect Dis. 2018 Jul;18(7):738-748. doi: 10.1016/S1473-3099(18)30165-8. Epub 2018 Apr 5. Lancet Infect Dis. 2018. PMID: 29627147 Free PMC article.
107 results